Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) said its MRI-guided, AI-powered TULSA-PRO incisionless prostate ablation will be featured at SRS2026 in Fort Lauderdale, July 23-26, with multiple physician presentations on registry and CAPTAIN trial outcomes. Profound also plans an investor session July 22 with Stifel and Wells Fargo analysts.
How this was made
The 30-second read
Why it matters
The text primarily announces conference presence and scheduled presentations (including CAPTAIN trial-related sessions) and an investor session moderated by Stifel and Wells Fargo analysts, but it does not disclose new quantitative outcomes or financial guidance.
Market read
Useful for timing and sentiment into SRS2026, but lacks new data or financial/regulatory catalysts.
What to watch
Traders may want to wait for any actual presentation materials or subsequent press releases that include new endpoints, adoption metrics, or payer/reimbursement developments.
Background
Profound is a commercial-stage interventional MRI device company with TULSA-PRO for incision-free prostate ablation and Sonalleve for MRI-guided therapy in other indications.
Ticker impact
Profound will highlight its MRI-guided, AI-powered TULSA procedure at SRS2026, including multiple CAPTAIN trial presentations and an investor session on July 22.
Near-term trading impact is likely limited to sentiment/attention ahead of SRS2026, absent new data, approvals, or commercial milestones.
The article is a promotional event schedule and company participation announcement. It references prior milestones (e.g., 100th procedure in 2022) and lists planned presentations, but does not provide new efficacy/safety numbers, regulatory actions, or revenue/forecast updates.
Market effects
Reinforces ongoing investor and clinician focus on image-guided, robotic, incisionless prostate ablation and AI-assisted workflows in medtech.
No specific regional demand or reimbursement change is disclosed.
Mentions global market clearances and international physician participation, but provides no new regulatory or commercial expansion details.
Counterpoint
Without new trial readouts, FDA/regulatory updates, or commercial traction metrics, the market may treat this as routine conference PR rather than a catalyst.
Key entities
- companyProfound Medical Corp.
NASDAQ-listed medical device company promoting its MRI-guided, AI-powered TULSA-PRO platform and TULSA procedure at SRS2026.
- eventSociety of Robotic Surgery (SRS)
Annual meeting in Fort Lauderdale, FL, July 23-26, 2026, where Profound’s procedure will be highlighted.
- organizationSociety of Incisionless Surgery (SIS)
Will spotlight eight companies during a plenary session at SRS2026, including Profound.
